The Capping Prescription Costs Act of 2025 creates a separate annual cap on cost‑sharing for prescription drugs: $2,000 per individual and $4,000 per family for plan years beginning in 2026, with those amounts indexed annually using the medical care component of the CPI‑U and rounded down to the nearest $5. The bill amends the Affordable Care Act’s qualified health plan rules and imposes parallel requirements on group health plans and issuers by adding provisions to the Public Health Service Act, ERISA, and the Internal Revenue Code.
This is a targeted affordability measure: it confines exposure at the pharmacy counter but leaves plans responsible for designing benefits and managing the bill’s downstream effects. For compliance teams, the bill creates a new line‑item obligation distinct from general out‑of‑pocket maxima and requires operational changes across market and employer plans before plan years starting January 1, 2026.
At a Glance
What It Does
The bill adds a prescription‑drug‑specific cost‑sharing ceiling to ACA qualified health plans and requires group health plans and issuers to follow the same dollar limits. After 2026 the statutory caps are increased each year by the medical‑care CPI‑U and rounded down to the nearest $5.
Who It Affects
Individual market enrollees in qualified health plans, employer‑sponsored group plan participants, health insurance issuers, and plan sponsors must redesign cost‑sharing flows to ensure pharmacy charges never exceed the statutory caps during a plan year.
Why It Matters
By singling out prescription drugs for a standalone annual cap, the bill shifts how plans manage specialty drug exposure, impacts premium and formulary strategies, and creates immediate operational deadlines for regulators and payers ahead of plan years beginning in 2026.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a new, standalone limit on how much an enrollee can be asked to pay out of pocket for prescription drugs in a single plan year. For plan years beginning in 2026 the statutory ceiling is $2,000 for each enrolled individual and $4,000 for each family.
Starting in 2027 the same base amounts are adjusted upward annually by the medical care component of the Consumer Price Index for All Urban Consumers (CPI‑U) and rounded down to the nearest $5.
Mechanically, the legislation modifies section 1302(c) of the Affordable Care Act to explicitly cover prescription drug cost‑sharing and to add the numeric caps. For employer and other group plans the bill achieves parity by inserting a new section into the Public Health Service Act and by adding parallel provisions to ERISA and the Internal Revenue Code, so that both insured and self‑insured group plans are subject to the same ceiling.The statute is written in plan‑year terms: obligations apply to plan years beginning on or after January 1, 2026.
The bill does not specify how payments from third parties (for example, manufacturer coupons) are credited toward the cap, nor does it alter other statutory out‑of‑pocket maximums; it creates a discrete requirement focused solely on prescription drug cost‑sharing. That leaves plan issuers and regulators to interpret how the new cap integrates with existing benefit designs, accumulator programs, and premium calculations.
The Five Things You Need to Know
The bill sets a prescription drug cost‑sharing cap of $2,000 per individual and $4,000 per family for plan years beginning in 2026.
After 2026 the caps increase annually by the medical care component of the CPI‑U (as published by BLS) and any increase is rounded down to the next lowest $5 increment.
It amends section 1302(c) of the ACA for qualified health plans and adds matching provisions to the Public Health Service Act (new sec. 2799A–6), ERISA (new sec. 721), and the Internal Revenue Code (new sec. 9821) to cover group plans.
The statutory obligation applies to health insurance issuers and group health plans — including self‑insured employer plans — rather than to only insured products.
The effective date is limited to plan years beginning on or after January 1, 2026; the bill does not prescribe administrative guidance or a specific enforcement penalty in the text.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Declares the Act’s common name: the Capping Prescription Costs Act of 2025. This is a technical header but signals the bill’s narrow focus on prescription drug cost‑sharing rather than broader insurance reforms.
Adds prescription drug cost‑sharing cap to qualified health plans
This provision inserts explicit language into section 1302(c) of the Affordable Care Act to treat prescription drug cost‑sharing as a covered form of charges and to create the dollar caps: $2,000 individual/$4,000 family in 2026. It also establishes the indexing rule for subsequent years using the medical care component of CPI‑U and specifies rounding down to the nearest $5. Practically, marketplace plans and any plan complying with ACA qualified health plan standards must ensure their pharmacy cost‑sharing calculations stop at the statutory cap for each enrollee during the plan year.
Extends the prescription cap to group health plans and issuers
Rather than relying on regulations alone, the bill creates statutory parity across plan types by adding: a new section 2799A–6 to the Public Health Service Act, a new section 721 to ERISA, and a new section 9821 to the Internal Revenue Code. Each new provision requires group health plans and health insurance issuers offering group coverage to ensure prescription drug cost‑sharing does not exceed the ACA cap. The coordinated insertion into those three statutes means insured and self‑insured employer plans, multiemployer plans, and issuers are all directly covered by the statutory ceiling.
Effective date and plan‑year application
The bill takes effect for plan years beginning on or after January 1, 2026. The text ties the obligation to plan years rather than calendar years, which matters for renewals and mid‑year changes: plans with non‑calendar plan years will need to apply the cap at the start of the first plan year that begins on or after the effective date.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- High‑need prescription drug patients: Individuals and families with substantial annual drug costs gain predictable, limited point‑of‑sale exposure, reducing the risk of catastrophic pharmacy bills for chronic and specialty therapies.
- Marketplace enrollees on ACA plans: People buying qualified health plans will see a legally guaranteed ceiling on drug cost‑sharing distinct from other out‑of‑pocket limits.
- Household budgets and financial counselors: The cap improves predictability for cash‑flow planning for households that would otherwise face variable or unlimited cost‑sharing across multiple fills.
Who Bears the Cost
- Health insurance issuers and group health plans: Plans must absorb or reallocate costs above the cap, which may raise claims costs and drive adjustments to premiums, formularies, or utilization management.
- Employers and plan sponsors: Particularly for employers who fund premiums, the increased drug cost burden may translate into higher premium contributions, benefit redesign, or shifts in employer financial exposure.
- Regulators and plan administrators: CMS, DOL, and Treasury (and downstream state regulators for fully insured products) must update guidance, oversight procedures, and enforcement approaches; plan administrators must change pharmacy adjudication systems and reconciliation processes.
Key Issues
The Core Tension
The central dilemma is protecting patients at the point of sale versus controlling overall health system costs: the bill makes drugs more affordable for individuals immediately but shifts financial pressure onto payers and employers, which can translate into higher premiums, tighter access controls, or changes in benefit design that may blunt the policy’s intended increase in drug affordability and access.
The bill tightly limits patient liability at the pharmacy counter but leaves many implementation choices unresolved. It does not define whether third‑party payments (manufacturer coupons, patient assistance programs, copay cards) must count toward the cap or whether accumulator adjustment practices are permissible; those omissions will determine how effectively the cap reduces consumer outlay.
The statute also does not specify enforcement mechanisms or penalties beyond relying on the existing enforcement frameworks in the ACA, ERISA, and tax law, which could produce uneven remedies or enforcement timelines across jurisdictions.
Indexing by the medical care component of CPI‑U keeps the caps responsive to general medical inflation but may diverge from prescription‑specific price trends — particularly for specialty drugs whose prices often outpace medical CPI. The rounding rule (rounding increases down to the next lowest $5) provides administrative simplicity but slightly erodes indexing gains.
Finally, because the bill places the financial burden on plans and issuers rather than on drug manufacturers or a direct financing mechanism, stakeholders should expect compensatory changes: higher premiums, narrower formularies, more aggressive utilization management, or slower uptake of expensive therapies that carry high total cost of care despite capped pharmacy charges.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.